Cite
HARVARD Citation
Tamura, K. et al. (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet oncology. 20 (6), pp. 816-826. [Online].